Adam Spjute, MD
Interventional Pain Medicine · Waco, TXNPI 1265851232
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 85.5% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $9,533, more than ten times the $647 reported in 2019.
Across 435 payments — averaging $53.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$20K
- Relievant Medsystems, Inc.$1K
- AbbVie$485
- Nevro Corp.$411
- Nalu Medical, Inc.$347
- Boston Scientific$282
- plus $456 from 12 others
What the payments were for
- Consulting fees$2,74812%
- Speaking & faculty fees$4,40019%
- Travel & lodging$4,15418%
- Food & beverage$11,91351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 334 | $19,837 |
| Relievant Medsystems, Inc. | 11 | $1,397 |
| AbbVie | 42 | $485 |
| Nevro Corp. | 4 | $411 |
| Nalu Medical, Inc. | 5 | $347 |
| Boston Scientific | 10 | $282 |
| Amgen | 5 | $97 |
| Medtronic(2 entities) | 6 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Biodelivery Sciences International, Inc. | 4 | $49 |
| Novartis | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Pfizer | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Stryker | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$12,032
- Intracept$4,134
- OCTRODE$2,022
- Proclaim IPG$494
- Nalu Neurostimulation System$263
- Senza Spinal Cord Stimulation System$251
- SPECTRA WAVEWRITER$119
How this compares
$23,215 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,765 | $128,281 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 509 | $12,747 |
| Xtampza ErOxycodone Myristate | 24 | $9,479 |
| Morphine Sulfate ErMorphine Sulfate | 341 | $7,367 |
| OxycontinOxycodone Hcl | 14 | $4,969 |
| Hydrocodone Bitartrate ErHydrocodone Bitartrate | 13 | $4,426 |
| Fentanyl | 31 | $2,703 |
| Gabapentin | 161 | $2,388 |
| Oxycodone Hcl | 162 | $1,890 |
| Tizanidine Hcl | 77 | $1,827 |
| Pregabalin | 81 | $1,727 |
| Naloxone Hcl | 13 | $878 |
| Tramadol Hcl ErTramadol Hcl | 14 | $845 |
| Hydromorphone Hcl | 86 | $826 |
| Tramadol Hcl | 89 | $739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $14 | $9,47924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Waco
- Shannon GarittyWaco$92K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.